CN105748467B - Pharmaceutical composition with effect of resisting lung cancer - Google Patents
Pharmaceutical composition with effect of resisting lung cancer Download PDFInfo
- Publication number
- CN105748467B CN105748467B CN201610075375.3A CN201610075375A CN105748467B CN 105748467 B CN105748467 B CN 105748467B CN 201610075375 A CN201610075375 A CN 201610075375A CN 105748467 B CN105748467 B CN 105748467B
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- acid
- tribute
- sutent
- effect
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention aims at providing a pharmaceutical composition with an effect of resisting lung cancer. The pharmaceutical composition is a compound containing sunitinib and smallanthus sonchifolius triptonoditerpenic acid. The pharmaceutical composition provided by the invention has an obvious anti-tumor effect.
Description
Technical field
The invention belongs to pharmaceutical technology field is and in particular to a kind of pharmaceutical composition of antitumor action.
Background technology
Pulmonary carcinoma is that M ＆ M increases the soonest, one of malignant tumor maximum to population health and life threat.
The many countries of immediate and mid-term all report that the M ＆ M of pulmonary carcinoma all substantially increases, and male lung cancer M ＆ M is equal
Account for first of all malignant tumor, women sickness rate accounts for second, mortality rate accounts for second.The cause of disease of pulmonary carcinoma is not still complete so far
Entirely clear and definite, great mass of data shows, a large amount of smokings for a long time have very close relationship with pulmonary carcinoma.Existing research has shown that:
The probability that a large amount of smokers suffer from pulmonary carcinoma for a long time is 10～20 times of non-smoker, and the age starting smoking is less, suffers from the several of pulmonary carcinoma
Rate is higher.Additionally, smoking not only directly affects my healthy, also harmful effect is produced to the health of surrounding population, lead
Involuntary smoker's pulmonary carcinoma prevalence is caused substantially to increase.
The sickness rate of urbanite's pulmonary carcinoma is higher than rural area, this may with urban atmospheric pollution and flue dust in contain carcinogen
Relevant.Serious all the more with nowadays haze, people also more pay attention to the concern of pulmonary carcinoma.
The clinical manifestation of pulmonary carcinoma is more complicated, and the morning and evening of the presence or absence of sings and symptoms, weight and appearance, depending on tumor
Happening part, histological type, have or not transfer and have or not complication, and the difference of reaction degree and toleration.Pulmonary carcinoma
Early symptom is often relatively slight, or even can no any discomfort.Early and weight in central type carcinoma of lung symptom, and peripheral type carcinoma of lung symptom occurs
Late and relatively light or even asymptomatic, often it is found in health check-up.
The treatment of pulmonary carcinoma has chemotherapy, radiotherapy and surgical intervention, and wherein, radiotherapy is a kind of local treatment, usually
Need combined chemotherapy；And surgical operation does not apply to all patients, therefore, chemotherapy is the primary treatments of pulmonary carcinoma,
More than 90% pulmonary carcinoma needs to accept chemotherapeutic treatment, and effect in pulmonary carcinoma for the chemotherapy in recent years has been no longer confined to inoperable late period
Patients with lung cancer, and the comprehensive therapeutic plan of pulmonary carcinoma is listed in frequently as whole body therapeutic.Develop effective pulmonary carcinoma chemicalses and there is weight
Want meaning.
Sutent is ratified treatment renal carcinoma prior to 2006 by U.S. fda, and in November, 2010 obtains EU Committee
Approval can be used to treat Pancreatic Neuroendocrine Tumors (pancreatic neuroendocrine tumors).2011
In May, U.S. fda also have approved Sutent for treating Pancreatic Neuroendocrine Tumors.Sutent also just at other very
Test in many tumors, including breast carcinoma, pulmonary carcinoma, thyroid carcinoma with connect intestinal cancer, but PRELIMINARY RESULTS shows: with such Drug therapy
Renal carcinoma is similar to, but has certain effect effect incomplete, not lasting.
Content of the invention
For above-mentioned prior art, present invention aim at provide a kind of pharmaceutical composition of antitumor action, be containing
Sutent and Yacon diterpene acid compounds.
Wherein Yacon diterpene acid compounds are the compounds extracting from plant Asia tribute, including sub- tribute diterpenoid acid a, Asia
Tribute diterpenoid acid b, sub- tribute diterpenoid acid c or sub- tribute diterpenoid acid d, its structure is as follows:
Further, described compositionss also include pharmaceutically acceptable carrier or excipient.
The mass ratio of described Sutent and Yacon diterpene acid compounds is (1-3): 6, preferably (2-2.5): 6.
Described combination dosage form is peroral dosage form.
Described compositionss are tablet or capsule.
Applicant find first Yacon diterpene acid compounds can effectively solving Sutent drug effect not exclusively, unabiding
Problem.Verified by animal and test cell line, Yacon diterpene acid compounds kill tumor cell to Sutent to be had
Huge cooperative effect, zooblast test all shows very successful experimental result, has significant antitumor curative effect.
Brief description
Fig. 1 is the result figure to a549 lung carcinoma cell therapeutic effect for the compositionss of the present invention.
Specific embodiment
Below in conjunction with specific embodiment, the present invention is described in detail, and described reagent no illustrates and is commercially available, reality
Testing animal model constructing method is: spf level balb/c Female nude mice, and weight is 18 ± 2g, and 4 week old, by lung adenocarcinoma cell
A549 cultivates to exponential phase, and pancreatin digests, is then diluted to cell suspension with serum-free medium, takes 1 × 106Individual
(1ml) to be inoculated in the right axil of balb/c nude mice subcutaneous for cell.The computational methods of tumor size, gross tumor volume v (mm3)=solid tumor is
Major diameter (mm) × solid tumor minor axis (mm)2/2.
Embodiment 1
Composite formula and compound method are as follows:
Weigh Sutent 10mg, sub- tribute diterpenoid acid a 60mg, add 50 microlitres of tween 80, be slowly added to normal saline
To 10ml.
Embodiment 2
Composite formula and compound method are as follows:
Weigh Sutent 30mg, sub- tribute diterpenoid acid b 60mg, add 50 microlitres of tween 80, be slowly added to normal saline
To 10ml.
Embodiment 3
Composite formula and compound method are as follows:
Weigh Sutent 20mg, sub- tribute diterpenoid acid a 60mg, add 50 microlitres of tween 80, be slowly added to normal saline
To 10ml.
Embodiment 4
Composite formula and compound method are as follows:
Weigh Sutent 25mg, sub- tribute diterpenoid acid c 60mg, add 50 microlitres of tween 80, be slowly added to normal saline
To 10ml.
Experiment one: to a549 lung carcinoma cell treatment effectiveness evaluation
Lung carcinoma cell a549 respectively with normal incubation medium (blank group), 200nm Asia tribute diterpenoid acid a, in Deficiency nutrition (be
The mechanism of action of Sutent, can be used for replacing it in the effect in test cell line) or normal condition under carry out respectively being incubated 48
Hour, wherein anoxia refers to oxygen content 0.5%, scarce trophonemata sugar-free, then analyzes the cellular level of survival, with the list of promega
Solution Cell Proliferation detection kit is analyzing.
Experimental result as shown in figure 1, when Sutent (Deficiency nutrition replacement) is combined with sub- tribute diterpenoid acid a, in pulmonary carcinoma
In cell a549, suppression ratio has reached 92%, has obvious cooperative effect.
Experiment two: in vivo antitumor effect
After model of nude mice bearing tumor sets up 7 days, it is randomly divided into 4 groups, every group 6, the compositionss tail prepared by Example 3 is quiet
Arteries and veins is administered, and administering mode is: isopyknic normal saline (matched group), injects embodiment 3 institute respectively by the injection volume of 4ml/kg
The sub- tribute diterpenoid acid a of the compositionss, the Sutent of 2mg/ml and 6mg/ml of preparation, observes the situation of tumor-bearing mice from the 7th day,
Lateral body weighs and gross tumor volume 2 times a week simultaneously, when matched group tumor size is more than 2000mm3When terminate observe, weigh, eyeball takes
Blood, cervical dislocation is put to death mice and is peeled off tumor, records knurl weight, knurl weight change is as shown in Figure 1.Tumor control rate computing formula:
Suppression ratio=[(matched group knurl weight-administration group knurl weight)/matched group knurl weight] × 100%, the results are shown in Table shown in 1.
Table 1 tumor control rate calculates
| Knurl weight (g) | Suppression ratio | |
| Matched group | 2.40±0.014 | 0 |
| Sutent | 1.65±0.312 | 31.25 |
| Sub- tribute diterpenoid acid a | 2.01+0.062 | 16.25 |
| Sutent+Asia tribute diterpenoid acid a | 0.37±0.089 | 84.58 |
By table 1 data, Sutent and Ya Gong diterpenoid acid a are used in combination, and have fabulous synergy, are in
Show significant antitumous effect.
Claims (6)
1. a kind of pharmaceutical composition of antitumor action is it is characterised in that contain Sutent and Yacon diterpene acid compounds；
Described Yacon diterpene acid compounds are sub- tribute diterpenoid acid a, sub- tribute diterpenoid acid b, sub- tribute diterpenoid acid c or sub- tribute diterpenoid acid d.
2. the pharmaceutical composition of antitumor action according to claim 1 is it is characterised in that described Sutent and Ya Gong
The mass ratio of diterpene acid is 1-3:6.
3. the pharmaceutical composition of antitumor action according to claim 2 is it is characterised in that described Sutent and Ya Gong
The mass ratio of diterpene acid is 2-2.5:6.
4. the pharmaceutical composition of antitumor action according to claim 1 is it is characterised in that described compositionss also include
Pharmaceutically acceptable carrier or excipient.
5. the pharmaceutical composition of antitumor action according to claim 1 is it is characterised in that described combination dosage form is
Peroral dosage form.
6. the pharmaceutical composition of antitumor action according to claim 5 is it is characterised in that described compositionss are tablet
Or capsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610075375.3A CN105748467B (en) | 2016-02-03 | 2016-02-03 | Pharmaceutical composition with effect of resisting lung cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610075375.3A CN105748467B (en) | 2016-02-03 | 2016-02-03 | Pharmaceutical composition with effect of resisting lung cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105748467A CN105748467A (en) | 2016-07-13 |
| CN105748467B true CN105748467B (en) | 2017-02-01 |
Family
ID=56330562
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610075375.3A Expired - Fee Related CN105748467B (en) | 2016-02-03 | 2016-02-03 | Pharmaceutical composition with effect of resisting lung cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105748467B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101225042A (en) * | 2008-02-18 | 2008-07-23 | 珍奥集团股份有限公司 | Yacon diterpene acid compounds, medicine composition, preparation method and use in preparation of medicine treating diabetes mellitus |
| CN103948689A (en) * | 2014-04-15 | 2014-07-30 | 西北农林科技大学 | Medicinal composition for treating non-small cell lung cancer and application thereof |
-
2016
- 2016-02-03 CN CN201610075375.3A patent/CN105748467B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101225042A (en) * | 2008-02-18 | 2008-07-23 | 珍奥集团股份有限公司 | Yacon diterpene acid compounds, medicine composition, preparation method and use in preparation of medicine treating diabetes mellitus |
| CN103948689A (en) * | 2014-04-15 | 2014-07-30 | 西北农林科技大学 | Medicinal composition for treating non-small cell lung cancer and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| 高效液相色谱-质谱法测定亚贡叶中亚贡二萜酸A和C的含量;吴振等;《厦门大学学报(自然科学版)》;20120131;第51卷(第1期);第72-76页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105748467A (en) | 2016-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Saleem et al. | Amygdalin from apricot kernels induces apoptosis and causes cell cycle arrest in cancer cells: an updated review | |
| White et al. | Effects of a mushroom mycelium extract on the treatment of prostate cancer | |
| CN105106959B (en) | Application and a kind of pharmaceutical composition of the cordycepin in the drug of preparation and radiotherapy and/or chemotherapy synergistic treatment tumour | |
| Itoh et al. | A Randomized, Double‐Blind Pilot Trial of Hydrolyzed Rice Bran versus Placebo for Radioprotective Effect on Acute Gastroenteritis Secondary to Chemoradiotherapy in Patients with Cervical Cancer | |
| TW201906633A (en) | Composition and method for improving chemical efficacy of cancer | |
| JP2016530281A (en) | Composition for prevention and treatment of cancer-related fatigue comprising processed ginseng powder or processed ginseng extract with increased ginsenoside component | |
| CN105748467B (en) | Pharmaceutical composition with effect of resisting lung cancer | |
| CN105380956B (en) | A kind of pharmaceutical composition of Dana Delany containing Chinese mugwort for treating leukaemia and application | |
| CN101773499A (en) | New applications of tetrahydropalmatine | |
| CN106163515A (en) | Anticancer and agents for relieving side effects | |
| CN109620828A (en) | Method for establishing model, model and the application of chemotherapy metenteron adverse reaction | |
| CN117797149A (en) | Application of Sidamide combined with R-CHOP and combined medicine | |
| CN109731019B (en) | A composition with chemotherapy synergistic effect comprises components, preparation and application | |
| Suprasert et al. | A randomized double blinded study of Ganoderma Lucidum (Lingzhi) in salvage setting of recurrent gynecologic cancer | |
| CN103800341B (en) | The combination medicine of anti-curing oncoma | |
| CN106138697B (en) | Chinese medicinal composition for preventing complications and relieving side effects of radiotherapy and chemotherapy of tumor patients | |
| CN106038566B (en) | A kind of pharmaceutical composition and its application for curing gastric cancer | |
| CN117045652B (en) | Application of kynurenic acid in preparation of medicine for relieving and/or treating bulimia nervosa | |
| CN104784651B (en) | A kind of method for preparing the pharmaceutical preparation for treating gastric ulcer | |
| CN103830262A (en) | Auxiliary drug used for treating cancer, and applications thereof | |
| CN109045052A (en) | For treating pharmaceutical formulation and the application of colon cancer | |
| CN102526033B (en) | Composition prepared from epigallocatechin gallate and mitomycin C and used for suppressing tumor cell proliferation | |
| Biskind | The relation of nutritional deficiency to impaired libido and potency in the male | |
| CN103385872B (en) | Pharmaceutical composition of a kind of Hepatoma therapy and preparation method thereof | |
| CN115779040A (en) | Traditional Chinese medicine composition for improving treatment effect of immune checkpoint inhibitor and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20170201 Termination date: 20180203 |